Seoul-based biotechnology company developing mRNA-encoded bispecific and multispecific antibodies delivered via lipid nanoparticles
Seoul-based biotechnology company developing mRNA-encoded bispecific and multispecific antibodies delivered via lipid nanoparticles. Its immuno-oncology platform is designed to engage patients’ natural killer (NK) cells and direct them to attack cancer cells.